AxoGen. has been granted a patent for customizable fasciculated nerve grafts, which are created by digesting the extracellular matrix around nerve fascicles. These grafts, designed to bridge nerve gaps, feature an entubulation material and are free from the epineurial sheath and native extracellular matrix. GlobalData’s report on AxoGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AxoGen, AI-assisted MRI was a key innovation area identified from patents. AxoGen's grant share as of June 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Customizable fasciculated nerve grafts for bridging nerve gaps
The granted patent US11998661B2 introduces a novel fasciculated nerve graft designed for use in nerve repair and regeneration. This graft comprises one or more nerve fascicles encased in an entubulation material made from a biocompatible substance. Notably, the graft is characterized by the absence of both the epineurial sheath and native extracellular matrix material, which are typically present in natural nerve tissues. The claims detail various configurations of the graft, including those with a single nerve fascicle or multiple fascicles, with specific parameters regarding their diameter (ranging from 50 µm to 1 mm) and length (between 3 mm and 200 mm). The graft may also include additional features such as a biodegradable coating, growth factors, or other cellular components to enhance its functionality.
The preparation method for the fasciculated nerve graft involves treating nerve tissue with enzymes to degrade the epineurial sheath and native extracellular matrix, followed by washing to remove residual enzymes and debris. This process results in nerve fascicles that are substantially free of unwanted materials, which are then entubulated in the biocompatible material. The patent emphasizes the potential for customization in the graft's composition, including the use of various biocompatible materials such as collagen, chitosan, and alginates, as well as the option to incorporate a seam sealed with a biocompatible adhesive. Overall, this patent presents a significant advancement in the field of nerve grafting, offering a versatile and tailored approach to nerve repair.
To know more about GlobalData’s detailed insights on AxoGen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
